drugset / Trial / NCT06549296

Clinical Study on Targeted CD19CAR-T Therapy for Autoimmune Diseases

NCT06549296

Phase 0 Suspended 12 enrolled Nanjing Bioheng Biotech Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, investigator-initiated clinical trial (IIT) aimed at evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of RD06-04 in patients with active SLE, SSc, AAV, IIM, and pSS

Timeline

Start
2024-09-13
Primary completion
2026-08-01
Completion
2027-08-01

Drugs

EvaluationDrugModalityDoseRoute
Subject RD06-04 Cell therapy Intravenous
Background Cyclophosphamide Other / unclassified
Background Fludarabine Small molecule